<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508884</url>
  </required_header>
  <id_info>
    <org_study_id>HKU-2012-432</org_study_id>
    <nct_id>NCT01508884</nct_id>
  </id_info>
  <brief_title>Intradermal Trivalent Influenza Vaccine With Imiquimod</brief_title>
  <official_title>Efficacy and Effectiveness of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod, a Double Blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the WHO International Health Regulations Emergency Committee declared an end to the&#xD;
      2009 H1N1 pandemic globally, the emergence of the novel 2009 H1N1 virus in March 2009 has&#xD;
      affected more than 214 countries with at least 18000 deaths [1]. Patients with chronic&#xD;
      underlying illness and extreme of ages are at risk of developing severe disease and&#xD;
      complications [2-3]. Resistance to oseltamivir has also been reported [4]. Therefore,&#xD;
      vaccination with the 2010/2011 trivalent influenza vaccine (TIV) with the 2009 H1N1-like&#xD;
      virus incorporated will be the best protection against the influenza infection, especially&#xD;
      among the at risk population. Recent study on dose sparing seasonal influenza vaccine&#xD;
      delivered via a novel intradermal microneedle has demonstrated good immunogenic responses&#xD;
      similar to full-dose intramuscular vaccination [6]. Poor immunogenicity of the H1N1 2009&#xD;
      component of the trivalent influenza has been reported [7].&#xD;
&#xD;
      Study has also suggested the combined intradermal vaccination with local stimulation of&#xD;
      dermal antigen presenting cells by applying imiquimod cream (Aldara) to the injection site,&#xD;
      which activate antigen presenting cells (APC) through the toll-like receptor 7 (TLR7) may&#xD;
      produce better immunogenicity [8].&#xD;
&#xD;
      Imiquimod cream is currently registered for the treatment of warts and basal cell carcinoma.&#xD;
      Scientific evidence has demonstrated that after treatment with imiquimod, the antigen is&#xD;
      processed and presented to cells of the adaptive immune system leading to clearance of the&#xD;
      virus and subsequent clearance of the lesions [9]. In addition to functional maturation,&#xD;
      imiquimod induces migration of dendritic cells from the dermis to draining lymph nodes&#xD;
      [10,11]. Subcutaneous administration of imiquimod as vaccine adjuvant simultaneously with the&#xD;
      antigen of interest, has shown to induce enhanced responses towards the administered antigen&#xD;
      [12].&#xD;
&#xD;
      We therefore performed a prospective, double blind, randomized controlled study to compare&#xD;
      the safety and immunogenicity between intradermal 2011/2012 TIV immunization with&#xD;
      pretreatment of imiquimod cream and conventional full dose intramuscular 2011/2012 TIV&#xD;
      immunization with pretreatment of aqueous cream as control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      References&#xD;
&#xD;
        1. World Health Organization. Influenza A (H1N1) - update 95 [cited 2010 April 10].&#xD;
           Available from http://www.who.int/csr/don/2009_12_30/en/index.html&#xD;
&#xD;
        2. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, et al. Infection and death from&#xD;
           influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374: 2072-9.&#xD;
&#xD;
        3. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization&#xD;
           due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:&#xD;
           1896-902.&#xD;
&#xD;
        4. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in&#xD;
           the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.&#xD;
&#xD;
        5. Chen H, Cheung CL, Tai H, et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009&#xD;
           virus, Hong Kong, China. Emerg Infect Dis 2009;15:1970-2.&#xD;
&#xD;
        6. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, et al. Safety and efficacy of a&#xD;
           novel microneedle device for dose sparing intradermal influenza vaccination in healthy&#xD;
           adults. Vaccine 2009;27:454-9&#xD;
&#xD;
        7. Myers CA, Faix DJ, Blair PJ. Possible reduced effectiveness of the 2009 H1N1 component&#xD;
           of live, attenuated influenza vaccine. Clin Infect Dis. 2011;15;53:207-8.9.&#xD;
&#xD;
        8. Roukens R, Vossen AC, Boland GJ, et al. Intradermal hepatitis B vaccination in&#xD;
           non-responders after topical application of imiquimod (Aldara). Vaccine 2010;4288-4293.&#xD;
&#xD;
        9. Tyring S, Conant M, Marini M, Van Der Meijden W, Washenik K. Imiquimod, an international&#xD;
           update on therapeutic uses in dermatology. Int J Dermatol 2002;41(11):810-6.&#xD;
&#xD;
       10. Burns Jr RP, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod&#xD;
           and R-848, induce functional, but not phenotypic, maturation of human epidermal&#xD;
           Langerhans' cells. Clin Immunol 2000;94(1):13-23.&#xD;
&#xD;
       11. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical&#xD;
           immune response modifier, induces migration of Langerhans cells. J Invest Dermatol&#xD;
           2000;114(1):135-41.&#xD;
&#xD;
       12. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse&#xD;
           model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.&#xD;
           Vaccine 2004;22(13-14):1799-809.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>day 7</time_frame>
    <description>The percentage of subjects with an hemagglutination inhibition antibody titre &lt;10 at baseline and a post-vaccination titre of ≥40 or a titre &gt;10 at baseline and at least a four-fold increase in titre post-vaccination on day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer old increase in influenza antibody titer</measure>
    <time_frame>day 21</time_frame>
    <description>The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assays on day 21 compared to day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate</measure>
    <time_frame>day 21</time_frame>
    <description>The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay on day 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (Immediate)</measure>
    <time_frame>30 minutes after vaccination</time_frame>
    <description>Patients who develop systemic or local adverse events within 30 minutes of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer old increase in influenza antibody titer</measure>
    <time_frame>day 7</time_frame>
    <description>The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay on day 7 compared to day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate</measure>
    <time_frame>day 7</time_frame>
    <description>The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay on day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer old increase in influenza antibody titer</measure>
    <time_frame>year 1</time_frame>
    <description>The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay at year 1 compared to day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate</measure>
    <time_frame>year 1</time_frame>
    <description>The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay at year 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>Year 1</time_frame>
    <description>The percentage of subjects with an hemagglutination inhibition antibody titre &lt;10 at baseline and a post-vaccination titre of ≥40 or a titre &gt;10 at baseline and at least a four-fold increase in titre post-vaccination at year 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (7 days)</measure>
    <time_frame>7 days after vaccination</time_frame>
    <description>Patients who develop systemic or local adverse events within 1 week of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>Day 21</time_frame>
    <description>The percentage of subjects with an hemagglutination inhibition antibody titre &lt;10 at baseline and a post-vaccination titre of ≥40 or a titre &gt;10 at baseline and at least a four-fold increase in titre post-vaccination on day 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer old increase in influenza antibody titer</measure>
    <time_frame>Day 14</time_frame>
    <description>The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay at year 1 compared to day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate</measure>
    <time_frame>Day 14</time_frame>
    <description>The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay at year 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>Day 14</time_frame>
    <description>The percentage of subjects with an hemagglutination inhibition antibody titre &lt;10 at baseline and a post-vaccination titre of ≥40 or a titre &gt;10 at baseline and at least a four-fold increase in titre post-vaccination at year 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>1 year post vaccination</time_frame>
    <description>hospitalization for pneumonia or influenza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>1 year post vaccination</time_frame>
    <description>Nasopharyngeal sample positive for influenza A</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Chronic Illness</condition>
  <arm_group>
    <arm_group_label>IM vaccine and placebo cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID vaccine and placebo cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID vaccine and imiquimod cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine</intervention_name>
    <description>single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine</description>
    <arm_group_label>ID vaccine and imiquimod cream</arm_group_label>
    <other_name>Intanza 15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>pretreatment with topical imiquimod cream to the injection site before vaccination</description>
    <arm_group_label>ID vaccine and imiquimod cream</arm_group_label>
    <other_name>Aldara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine</intervention_name>
    <description>single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine</description>
    <arm_group_label>ID vaccine and placebo cream</arm_group_label>
    <other_name>Intanza 15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aqueous cream</intervention_name>
    <description>pretreatment with topical aqueous cream to the injection site before vaccination</description>
    <arm_group_label>ID vaccine and placebo cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine</intervention_name>
    <description>single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine</description>
    <arm_group_label>IM vaccine and placebo cream</arm_group_label>
    <other_name>Vaxigrip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aqueous cream</intervention_name>
    <description>pretreatment with topical aqueous cream to the injection site before vaccination</description>
    <arm_group_label>IM vaccine and placebo cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult patients at the age of 21 or above with chronic illness and given written&#xD;
             informed consent&#xD;
&#xD;
          -  Subjects must be available to complete the study and comply with study procedures.&#xD;
             Willingness to allow for serum samples to be stored beyond the study period, for&#xD;
             potential additional future testing to better characterize immune response.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant immune-related diseases or significant recent co-morbidities&#xD;
&#xD;
          -  Inability to comprehend and to follow all required study procedures&#xD;
&#xD;
          -  History or any illness that might interfere with the results of the study or pose&#xD;
             additional risk to the subjects due to participation in the study&#xD;
&#xD;
          -  Have received 2011/2012 TIV&#xD;
&#xD;
          -  Have a recent history (documented, confirmed or suspected) of a flu-like disease&#xD;
             within a week of vaccination.&#xD;
&#xD;
          -  Have a known allergy to eggs or other components of the Study Vaccines (including&#xD;
             gelatin, formaldehyde, octoxinol, thimerosal, and chicken protein), or history of any&#xD;
             anaphylaxis, serious vaccine reactions, to any excipients.&#xD;
&#xD;
          -  Have a positive urine or serum pregnancy test within 24 hours prior to vaccination, or&#xD;
             women who are breastfeeding.&#xD;
&#xD;
          -  Female of childbearing potential, not using any acceptable contraceptive methods for&#xD;
             at least 2 months prior to study entry or that do not plan to use acceptable birth&#xD;
             control measures during the first 3 weeks after vaccination.&#xD;
&#xD;
          -  Have immunosuppression as a result of an underlying illness or treatment, or use of&#xD;
             anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36&#xD;
             months.&#xD;
&#xD;
          -  Have an active neoplastic disease or a history of any hematologic malignancy.&#xD;
&#xD;
          -  Have long-term use of glucocorticoids including oral, parenteral or high-dose inhaled&#xD;
             steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent) within the&#xD;
             preceding 6 months. (Nasal and topical steroids are allowed).&#xD;
&#xD;
          -  Have a history of receiving immunoglobulin or other blood product within the 3 months&#xD;
             prior to vaccination in this study.&#xD;
&#xD;
          -  Have known active human immunodeficiency virus (HIV) infection, acute hepatitis B or C&#xD;
             infection, autoimmune hepatitis and related cirrhosis&#xD;
&#xD;
          -  Received an experimental agent (vaccine, drug, biologic, device, blood product, or&#xD;
             medication) within 1 month prior to vaccination in this study or expect to receive an&#xD;
             experimental agent during this study. Unwilling to refuse participation in another&#xD;
             clinical study through the end of this study.&#xD;
&#xD;
          -  History of progressive or severe neurological disorders&#xD;
&#xD;
          -  Have received any licensed vaccines within 4 weeks or inactivated licensed vaccines&#xD;
             within 2 weeks prior to vaccination in this study or plan receipt of such vaccines&#xD;
             within 21 days following the second vaccination (only exception being unadjuvanted&#xD;
             seasonal influenza vaccines which are allowed until 1 week prior to and after 1 week&#xD;
             study vaccinations).&#xD;
&#xD;
          -  Axillary temperature ≥ 38°C or oral temperature ≥ 38.5°C within 3 days of intended&#xD;
             study vaccination&#xD;
&#xD;
          -  Surgery planned during the study period that in the Investigator's opinion would&#xD;
             interfere with the study visits schedule&#xD;
&#xD;
          -  Have a history of alcohol or drug abuse in the last 5 years.&#xD;
&#xD;
          -  Have a history of Guillain-Barré Syndrome.&#xD;
&#xD;
          -  Have any condition that the investigator believes may interfere with successful&#xD;
             completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan FN Hung, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Hong Kong, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>December 8, 2013</last_update_submitted>
  <last_update_submitted_qc>December 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr Ivan FN Hung</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>intradermal</keyword>
  <keyword>influenza</keyword>
  <keyword>vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

